Header Logo

Connection

KAREN RABIN to Humans

Back to Details
This is a "connection" page, showing publications KAREN RABIN has written about Humans.
KAREN RABIN
Connection Strength
0.783
Humans
  1. Outcomes in Children, Adolescents, and Young Adults With Down Syndrome and ALL: A Report From the Children's Oncology Group. J Clin Oncol. 2024 Jan 10; 42(2):218-227.
    View in: PubMed
    Score: 0.024
  2. Management of Down Syndrome-Associated Leukemias: A Review. JAMA Oncol. 2023 09 01; 9(9):1283-1290.
    View in: PubMed
    Score: 0.024
  3. Insights into the genomics of iAMP21-ALL. Blood. 2023 08 24; 142(8):682-684.
    View in: PubMed
    Score: 0.024
  4. Patients with Down syndrome can be included in early phase clinical trials- a report from the T2016-003 Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) study. Leukemia. 2023 05; 37(5):1138-1140.
    View in: PubMed
    Score: 0.023
  5. Genetic Ancestry and Childhood Acute Lymphoblastic Leukemia Subtypes and Outcomes in the Genomic Era. JAMA Oncol. 2022 03 01; 8(3):342-343.
    View in: PubMed
    Score: 0.021
  6. Risk stratification for Down syndrome and acute lymphocytic leukaemia: one size does not fit all. Lancet Haematol. 2021 Oct; 8(10):e673-e675.
    View in: PubMed
    Score: 0.021
  7. Enhancer polymorphisms at the IKZF1 susceptibility locus for acute lymphoblastic leukemia impact B-cell proliferation and differentiation in both Down syndrome and non-Down syndrome genetic backgrounds. PLoS One. 2021; 16(1):e0244863.
    View in: PubMed
    Score: 0.020
  8. Optimizing Targeted Therapy for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. JAMA Oncol. 2020 03 01; 6(3):333-334.
    View in: PubMed
    Score: 0.019
  9. Need for new thinking: Treatment of relapsed leukemia in children with Down syndrome. Pediatr Blood Cancer. 2019 06; 66(6):e27644.
    View in: PubMed
    Score: 0.017
  10. Self-reported adherence in ALL: true or false? Blood. 2017 04 06; 129(14):1888-1889.
    View in: PubMed
    Score: 0.015
  11. Ethnic disparities relative to disease features and outcomes in children with acute myeloid leukemia. Pediatr Blood Cancer. 2017 Sep; 64(9).
    View in: PubMed
    Score: 0.015
  12. First do no harm: infectious deaths in pediatric ALL. Blood. 2014 Aug 14; 124(7):987-9.
    View in: PubMed
    Score: 0.013
  13. Reply to "Peripheral blood lymphocyte recovery and overall survival in pediatric acute lymphoblastic leukemia". Pediatr Blood Cancer. 2014 Jan; 61(1):180.
    View in: PubMed
    Score: 0.012
  14. The adolescent and young adult with cancer: state of the art-- acute leukemias. Curr Oncol Rep. 2013 Aug; 15(4):317-24.
    View in: PubMed
    Score: 0.012
  15. Attacking remaining challenges in childhood leukemia. N Engl J Med. 2012 Apr 12; 366(15):1445-6.
    View in: PubMed
    Score: 0.011
  16. Myelosuppression and infectious complications in children with Down syndrome and acute lymphoblastic leukemia. Pediatr Blood Cancer. 2012 Apr; 58(4):633-5.
    View in: PubMed
    Score: 0.010
  17. Absolute lymphocyte counts refine minimal residual disease-based risk stratification in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2012 Sep; 59(3):468-74.
    View in: PubMed
    Score: 0.010
  18. Genomic profiling in Down syndrome acute lymphoblastic leukemia identifies histone gene deletions associated with altered methylation profiles. Leukemia. 2011 Oct; 25(10):1555-63.
    View in: PubMed
    Score: 0.010
  19. Management strategies in acute lymphoblastic leukemia. Oncology (Williston Park). 2011 Apr 15; 25(4):328-35.
    View in: PubMed
    Score: 0.010
  20. Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet. 2009 Nov; 41(11):1243-6.
    View in: PubMed
    Score: 0.009
  21. Malignancy in children with trisomy 21. Oncologist. 2009 Feb; 14(2):164-73.
    View in: PubMed
    Score: 0.009
  22. Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia. Br J Haematol. 2009 Mar; 144(6):930-2.
    View in: PubMed
    Score: 0.009
  23. Differential in vitro cytotoxicity does not explain increased host toxicities from chemotherapy in Down syndrome acute lymphoblastic leukemia. Leuk Res. 2009 Feb; 33(2):336-9.
    View in: PubMed
    Score: 0.008
  24. Clinical utility of array comparative genomic hybridization for detection of chromosomal abnormalities in pediatric acute lymphoblastic leukemia. Pediatr Blood Cancer. 2008 Aug; 51(2):171-7.
    View in: PubMed
    Score: 0.008
  25. Personalized care of pediatric cancer patients. Nestle Nutr Workshop Ser Pediatr Program. 2008; 62:173-85; discussion 185-8.
    View in: PubMed
    Score: 0.008
  26. Genome-Wide Association Studies of Down Syndrome Associated Congenital Heart Defects Suggests a Genetically Heterogeneous Risk for CHD in DS. Genet Epidemiol. 2025 Jun; 49(4):e70010.
    View in: PubMed
    Score: 0.007
  27. Performance of Two-Phase Designs for the Time-to-Event Outcome and a Case Study Assessing the Relapse Risk Associated With B-ALL Subtypes. JCO Clin Cancer Inform. 2025 May; 9:e2400223.
    View in: PubMed
    Score: 0.007
  28. Ultra-low extracorporeal volume microfluidic leukapheresis is safe and effective in a rat model. Nat Commun. 2025 Feb 24; 16(1):1930.
    View in: PubMed
    Score: 0.007
  29. Imagine, Discover, Inspire: Proceedings of the 4th International Conference of the Trisomy 21 Research Society. Neuromolecular Med. 2025 Jan 05; 27(1):5.
    View in: PubMed
    Score: 0.006
  30. Evaluation of methotrexate Pharmacogenomic variation to predict acute neurotoxicity in children with acute lymphoblastic leukemia. Pharmacotherapy. 2025 Jan; 45(1):4-11.
    View in: PubMed
    Score: 0.006
  31. Co-targeting of the thymic stromal lymphopoietin receptor to decrease immunotherapeutic resistance in CRLF2-rearranged Ph-like and Down syndrome acute lymphoblastic leukemia. Leukemia. 2025 Mar; 39(3):555-567.
    View in: PubMed
    Score: 0.006
  32. Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children. N Engl J Med. 2025 Feb 27; 392(9):875-891.
    View in: PubMed
    Score: 0.006
  33. Automated Electronic Health Record Data Extraction and Curation Using ExtractEHR. JCO Clin Cancer Inform. 2024 Nov; 8:e2400100.
    View in: PubMed
    Score: 0.006
  34. Delayed excretion of high-dose methotrexate in pediatric acute leukemia correlates with laxative and constipation management. Pediatr Blood Cancer. 2025 Jan; 72(1):e31377.
    View in: PubMed
    Score: 0.006
  35. Cerebral Sinus Venous Thrombosis in Pediatric Acute Lymphoblastic Leukemia: Incidence, Clinical Characteristics, and Long-term Neurologic Outcomes. J Child Neurol. 2024 Nov; 39(13-14):494-499.
    View in: PubMed
    Score: 0.006
  36. Genomic Determinants of Outcome in Acute Lymphoblastic Leukemia. J Clin Oncol. 2024 Oct 10; 42(29):3491-3503.
    View in: PubMed
    Score: 0.006
  37. Episodes of acute methotrexate-related neurotoxicity linked to compromised long-term neurocognitive function. Pediatr Blood Cancer. 2024 Sep; 71(9):e31169.
    View in: PubMed
    Score: 0.006
  38. Enhanced Risk Stratification for Children and Young Adults with B-Cell Acute Lymphoblastic Leukemia: A Children's Oncology Group Report. Leukemia. 2024 04; 38(4):720-728.
    View in: PubMed
    Score: 0.006
  39. Prognostic significance of ETP phenotype and minimal residual disease in T-ALL: a Children's Oncology Group study. Blood. 2023 12 14; 142(24):2069-2078.
    View in: PubMed
    Score: 0.006
  40. Survival outcomes of children with relapsed or refractory myeloid leukemia associated with Down syndrome. Blood Adv. 2023 11 14; 7(21):6532-6539.
    View in: PubMed
    Score: 0.006
  41. Racial and ethnic disparities in acuity of presentation among children with newly diagnosed acute leukemia. Pediatr Blood Cancer. 2024 Jan; 71(1):e30726.
    View in: PubMed
    Score: 0.006
  42. Down syndrome and leukemia: from basic mechanisms to clinical advances. Haematologica. 2023 10 01; 108(10):2570-2581.
    View in: PubMed
    Score: 0.006
  43. Acute and chronic kidney injury during therapy for pediatric acute leukemia: A report from the Leukemia Electronic Abstraction of Records Network (LEARN). Pediatr Blood Cancer. 2023 Dec; 70(12):e30696.
    View in: PubMed
    Score: 0.006
  44. Flow cytometric assessment of leukemia-associated monocytes in childhood B-cell acute lymphoblastic leukemia outcome. Blood Adv. 2023 08 08; 7(15):3928-3931.
    View in: PubMed
    Score: 0.006
  45. Children's Oncology Group blueprint for research: Acute lymphoblastic leukemia. Pediatr Blood Cancer. 2023 09; 70 Suppl 6:e30585.
    View in: PubMed
    Score: 0.006
  46. Central nervous system status is prognostic in T-cell acute lymphoblastic leukemia: a Children's Oncology Group report. Blood. 2023 04 13; 141(15):1802-1811.
    View in: PubMed
    Score: 0.006
  47. Outstanding outcomes with two low intensity regimens in children with low-risk B-ALL: a report from COG AALL0932. Leukemia. 2023 06; 37(6):1375-1378.
    View in: PubMed
    Score: 0.006
  48. Prognostic impact of pretreatment immunoglobulin clonal composition in pediatric B-lymphoblastic leukemia. Haematologica. 2023 03 01; 108(3):900-904.
    View in: PubMed
    Score: 0.006
  49. Novel and replicated clinical and genetic risk factors for toxicity from high-dose methotrexate in pediatric acute lymphoblastic leukemia. Pharmacotherapy. 2023 03; 43(3):205-214.
    View in: PubMed
    Score: 0.006
  50. Antileukemic properties of the kinase inhibitor OTSSP167 in T-cell acute lymphoblastic leukemia. Blood Adv. 2023 02 14; 7(3):422-435.
    View in: PubMed
    Score: 0.006
  51. Racial and ethnic disparities in childhood and young adult acute lymphocytic leukaemia: secondary analyses of eight Children's Oncology Group cohort trials. Lancet Haematol. 2023 Feb; 10(2):e129-e141.
    View in: PubMed
    Score: 0.006
  52. Ethnic-specific predictors of neurotoxicity among patients with pediatric acute lymphoblastic leukemia after high-dose methotrexate. Cancer. 2023 04 15; 129(8):1287-1294.
    View in: PubMed
    Score: 0.006
  53. Absolute lymphocyte count recovery following initial acute myelogenous leukemia therapy: Implications for adoptive cell therapy. Pediatr Blood Cancer. 2023 01; 70(1):e30062.
    View in: PubMed
    Score: 0.006
  54. Improving infectious adverse event reporting for children and adolescents enrolled in clinical trials for acute lymphoblastic leukemia: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2022 11; 69(11):e29937.
    View in: PubMed
    Score: 0.006
  55. The genomic landscape of pediatric acute lymphoblastic leukemia. Nat Genet. 2022 09; 54(9):1376-1389.
    View in: PubMed
    Score: 0.006
  56. Epigenome-wide association study of acute lymphoblastic leukemia in children with Down syndrome. Blood Adv. 2022 07 26; 6(14):4132-4136.
    View in: PubMed
    Score: 0.005
  57. Rates of laboratory adverse events by course in paediatric leukaemia ascertained with automated electronic health record extraction: a retrospective cohort study from the Children's Oncology Group. Lancet Haematol. 2022 Sep; 9(9):e678-e688.
    View in: PubMed
    Score: 0.005
  58. A report from the Leukemia Electronic Abstraction of Records Network on risk of hepatotoxicity during pediatric acute lymphoblastic leukemia treatment. Haematologica. 2022 05 01; 107(5):1185-1188.
    View in: PubMed
    Score: 0.005
  59. An updated assessment of 43,110 patients enrolled in the Childhood Cancer Research Network: A Children's Oncology Group report. Cancer. 2022 07 15; 128(14):2760-2767.
    View in: PubMed
    Score: 0.005
  60. CRLF2 overexpression results in reduced B-cell differentiation and upregulated E2F signaling in the Dp16 mouse model of Down syndrome. Exp Hematol. 2022 06; 110:34-38.
    View in: PubMed
    Score: 0.005
  61. Residence in a Latinx enclave and end-induction minimal residual disease positivity among children with acute lymphoblastic leukemia. Pediatr Hematol Oncol. 2022 Oct; 39(7):650-657.
    View in: PubMed
    Score: 0.005
  62. Sex-based disparities in outcome in pediatric acute lymphoblastic leukemia: a Children's Oncology Group report. Cancer. 2022 05 01; 128(9):1863-1870.
    View in: PubMed
    Score: 0.005
  63. Outcomes in adolescent and young adult patients (16 to 30 years) compared to younger patients treated for high-risk B-lymphoblastic leukemia: report from Children's Oncology Group Study AALL0232. Leukemia. 2022 03; 36(3):648-655.
    View in: PubMed
    Score: 0.005
  64. Comparison of the blood, bone marrow, and cerebrospinal fluid metabolomes in children with b-cell acute lymphoblastic leukemia. Sci Rep. 2021 10 04; 11(1):19613.
    View in: PubMed
    Score: 0.005
  65. Association of Combined Focal 22q11.22 Deletion and IKZF1 Alterations With Outcomes in Childhood Acute Lymphoblastic Leukemia. JAMA Oncol. 2021 Oct 01; 7(10):1521-1528.
    View in: PubMed
    Score: 0.005
  66. An evidence-based, risk-adapted algorithm for antifungal prophylaxis reduces risk for invasive mold infections in children with hematologic malignancies. Pediatr Blood Cancer. 2021 12; 68(12):e29228.
    View in: PubMed
    Score: 0.005
  67. Converging genetic and epigenetic drivers of paediatric acute lymphoblastic leukaemia identified by an information-theoretic analysis. Nat Biomed Eng. 2021 04; 5(4):360-376.
    View in: PubMed
    Score: 0.005
  68. Novel risk factors for glucarpidase use in pediatric acute lymphoblastic leukemia: Hispanic ethnicity, age, and the ABCC4 gene. Pediatr Blood Cancer. 2021 08; 68(8):e29036.
    View in: PubMed
    Score: 0.005
  69. Prognostic impact of minimal residual disease at the end of consolidation in NCI standard-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2021 04; 68(4):e28929.
    View in: PubMed
    Score: 0.005
  70. Molecular basis of ETV6-mediated predisposition to childhood acute lymphoblastic leukemia. Blood. 2021 01 21; 137(3):364-373.
    View in: PubMed
    Score: 0.005
  71. Excellent Outcomes With Reduced Frequency of Vincristine and Dexamethasone Pulses in Standard-Risk B-Lymphoblastic Leukemia: Results From Children's Oncology Group AALL0932. J Clin Oncol. 2021 05 01; 39(13):1437-1447.
    View in: PubMed
    Score: 0.005
  72. The relationship between chronic health conditions and cognitive deficits in children, adolescents, and young adults with down syndrome: A systematic review. PLoS One. 2020; 15(9):e0239040.
    View in: PubMed
    Score: 0.005
  73. Aberrant leukemia-associated immunophenotype as potential harbinger of lineage switch in KMT2A-rearranged leukemia: a case series. Leuk Lymphoma. 2020 12; 61(14):3515-3518.
    View in: PubMed
    Score: 0.005
  74. Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2020 10 01; 38(28):3282-3293.
    View in: PubMed
    Score: 0.005
  75. Area deprivation is associated with poorer overall survival in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2020 09; 67(9):e28525.
    View in: PubMed
    Score: 0.005
  76. Impact of Intrathecal Triple Therapy Versus Intrathecal Methotrexate on Disease-Free Survival for High-Risk B-Lymphoblastic Leukemia: Children's Oncology Group Study AALL1131. J Clin Oncol. 2020 08 10; 38(23):2628-2638.
    View in: PubMed
    Score: 0.005
  77. Six Candidate miRNAs Associated With Early Relapse in Pediatric B-Cell Acute Lymphoblastic Leukemia. Anticancer Res. 2020 Jun; 40(6):3147-3153.
    View in: PubMed
    Score: 0.005
  78. Extensive Remodeling of the Immune Microenvironment in B Cell Acute Lymphoblastic Leukemia. Cancer Cell. 2020 06 08; 37(6):867-882.e12.
    View in: PubMed
    Score: 0.005
  79. Identifying relapses and stem cell transplants in pediatric acute lymphoblastic leukemia using administrative data: Capturing national outcomes irrespective of trial enrollment. Pediatr Blood Cancer. 2021 09; 68(9):e28315.
    View in: PubMed
    Score: 0.005
  80. Utilization of archived neonatal dried blood spots for genome-wide genotyping. PLoS One. 2020; 15(2):e0229352.
    View in: PubMed
    Score: 0.005
  81. Significance of minimal residual disease in pediatric mixed phenotype acute leukemia: a multicenter cohort study. Leukemia. 2020 07; 34(7):1741-1750.
    View in: PubMed
    Score: 0.005
  82. Genome-Wide Association Study of Susceptibility Loci for T-Cell Acute Lymphoblastic Leukemia in Children. J Natl Cancer Inst. 2019 12 01; 111(12):1350-1357.
    View in: PubMed
    Score: 0.005
  83. Mixed-phenotype acute leukemia: A cohort and consensus research strategy from the Children's Oncology Group Acute Leukemia of Ambiguous Lineage Task Force. Cancer. 2020 02 01; 126(3):593-601.
    View in: PubMed
    Score: 0.005
  84. Metabolomic profiling identifies pathways associated with minimal residual disease in childhood acute lymphoblastic leukaemia. EBioMedicine. 2019 Oct; 48:49-57.
    View in: PubMed
    Score: 0.005
  85. Inherited genetic susceptibility to acute lymphoblastic leukemia in Down syndrome. Blood. 2019 10 10; 134(15):1227-1237.
    View in: PubMed
    Score: 0.005
  86. Excellent long-term survival of children with Down syndrome and standard-risk ALL: a report from the Children's Oncology Group. Blood Adv. 2019 06 11; 3(11):1647-1656.
    View in: PubMed
    Score: 0.004
  87. Maternal Residential Proximity to Major Roadways and the Risk of Childhood Acute Leukemia: A Population-Based Case-Control Study in Texas, 1995-2011. Int J Environ Res Public Health. 2019 06 07; 16(11).
    View in: PubMed
    Score: 0.004
  88. PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. Nat Genet. 2019 02; 51(2):296-307.
    View in: PubMed
    Score: 0.004
  89. Replacing cyclophosphamide/cytarabine/mercaptopurine with cyclophosphamide/etoposide during consolidation/delayed intensification does not improve outcome for pediatric B-cell acute lymphoblastic leukemia: a report from the COG. Haematologica. 2019 05; 104(5):986-992.
    View in: PubMed
    Score: 0.004
  90. PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia. J Exp Med. 2018 12 03; 215(12):3094-3114.
    View in: PubMed
    Score: 0.004
  91. Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children's Oncology Group AALL0434 Methotrexate Randomization. J Clin Oncol. 2018 10 10; 36(29):2926-2934.
    View in: PubMed
    Score: 0.004
  92. Maternal folate genes and aberrant DNA hypermethylation in pediatric acute lymphoblastic leukemia. PLoS One. 2018; 13(5):e0197408.
    View in: PubMed
    Score: 0.004
  93. An overview of disparities in childhood cancer: Report on the Inaugural Symposium on Childhood Cancer Health Disparities, Houston, Texas, 2016. Pediatr Hematol Oncol. 2018 Mar; 35(2):95-110.
    View in: PubMed
    Score: 0.004
  94. International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia. Blood. 2018 07 19; 132(3):264-276.
    View in: PubMed
    Score: 0.004
  95. Preclinical evaluation of NUDT15-guided thiopurine therapy and its effects on toxicity and antileukemic efficacy. Blood. 2018 05 31; 131(22):2466-2474.
    View in: PubMed
    Score: 0.004
  96. Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II Trial. J Clin Oncol. 2018 05 01; 36(13):1330-1338.
    View in: PubMed
    Score: 0.004
  97. Family-based exome-wide association study of childhood acute lymphoblastic leukemia among Hispanics confirms role of ARID5B in susceptibility. PLoS One. 2017; 12(8):e0180488.
    View in: PubMed
    Score: 0.004
  98. Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group. Blood. 2017 06 22; 129(25):3352-3361.
    View in: PubMed
    Score: 0.004
  99. Inactivation of KLF4 promotes T-cell acute lymphoblastic leukemia and activates the MAP2K7 pathway. Leukemia. 2017 06; 31(6):1314-1324.
    View in: PubMed
    Score: 0.004
  100. Family-based exome-wide assessment of maternal genetic effects on susceptibility to childhood B-cell acute lymphoblastic leukemia in hispanics. Cancer. 2016 Dec 01; 122(23):3697-3704.
    View in: PubMed
    Score: 0.004
  101. The TGF-?/SMAD pathway is an important mechanism for NK cell immune evasion in childhood B-acute lymphoblastic leukemia. Leukemia. 2016 Apr; 30(4):800-11.
    View in: PubMed
    Score: 0.003
  102. Adult Low-Hypodiploid Acute B-Lymphoblastic Leukemia With IKZF3 Deletion and TP53 Mutation: Comparison With Pediatric Patients. Am J Clin Pathol. 2015 Aug; 144(2):263-70.
    View in: PubMed
    Score: 0.003
  103. A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011). Pediatr Blood Cancer. 2015 Oct; 62(10):1717-24.
    View in: PubMed
    Score: 0.003
  104. Integration of cytogenomic data for furthering the characterization of pediatric B-cell acute lymphoblastic leukemia: a multi-institution, multi-platform microarray study. Cancer Genet. 2015 Jan-Feb; 208(1-2):1-18.
    View in: PubMed
    Score: 0.003
  105. Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group. Blood. 2014 Jan 02; 123(1):70-7.
    View in: PubMed
    Score: 0.003
  106. G0S2 inhibits the proliferation of K562 cells by interacting with nucleolin in the cytosol. Leuk Res. 2014 Feb; 38(2):210-7.
    View in: PubMed
    Score: 0.003
  107. Generation of tumor antigen-specific T cell lines from pediatric patients with acute lymphoblastic leukemia--implications for immunotherapy. Clin Cancer Res. 2013 Sep 15; 19(18):5079-91.
    View in: PubMed
    Score: 0.003
  108. Generation of multi-leukemia antigen-specific T cells to enhance the graft-versus-leukemia effect after allogeneic stem cell transplant. Leukemia. 2013 Jul; 27(7):1538-47.
    View in: PubMed
    Score: 0.003
  109. Pediatric Hodgkin lymphoma: are we over-scanning our patients? Pediatr Hematol Oncol. 2012 Aug; 29(5):415-23.
    View in: PubMed
    Score: 0.003
  110. Frequency and prognostic implications of JAK 1-3 aberrations in Down syndrome acute lymphoblastic and myeloid leukemia. Leukemia. 2011 Aug; 25(8):1365-8.
    View in: PubMed
    Score: 0.003
  111. Conditional animal models: a strategy to define when oncogenes will be effective targets to treat cancer. Semin Cancer Biol. 2004 Feb; 14(1):3-11.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.